Comparative studies with surface plasmon resonance and free oscillation rheometry on the inhibition of platelets with cytochalasin E and monoclonal antibodies towards GPIIb/IIIa.
In the haemostatic system a multitude of processes are intertwined in fine-tuned interactions that arrest bleeding, keep the circulatory system open, and the blood flowing. The occurrence of both surface and bulk interactions adds an additional dimension of complexity. These insights have led to the belief that global overall procedures can inform on the likely behaviour of the system in health and disease. Two sensing procedures: surface plasmon resonance (SPR), which senses surface interactions, and free oscillation rheometry (FOR), which senses interactions within the bulk, have been combined and evaluated. The contribution of blood cells, mainly platelets, to the SPR and FOR signals was explored by simultaneous SPR and FOR measurement during native whole blood coagulation, accelerated via the platelets through addition of SFLLRN peptide and inhibition of platelet aggregation with abciximab (ReoPro) and of shape change with cytochalasin E. The SPR technique was found to be sensitive to inhibition of blood cell functions such as adhesion to and spreading on surfaces, as well as platelet aggregation. SPR seemed not to be directly sensitive to fibrin polymerisation in coagulating whole blood. The FOR technique detected the coagulation as a bulk phenomenon, i.e. the gelation of the blood due to fibrin formation was detected. The combination of SPR and FOR may therefore be suitable for studies on blood cell functions during coagulation.
Hansson
Kenny M
KM
Department of Biomedicine and Surgery, Division of Clinical Chemistry, Linköping University Hospital, SE-581 85, Linköping, Sweden. kenny.m.hansson@astrazeneca.com
Tengvall
Pentti
P
Lundström
Ingemar
I
Rånby
Mats
M
Lindahl
Tomas L
TL
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D001672:Biocompatible Materials; D001769:Blood / Q000187:drug effects; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D002448:Cell Adhesion; D003572:Cytochalasins / Q000494:pharmacology*; D005240:Feasibility Studies; D005342:Fibrinolysis; D018056:Hemorheology / Q000295:instrumentation / Q000379:methods*; D006487:Hemostasis; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology*; D008422:Materials Testing / Q000295:instrumentation / Q000379:methods; D009991:Oscillometry / Q000295:instrumentation / Q000379:methods; D010949:Plasma; D010974:Platelet Aggregation / Q000187:drug effects*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors / Q000494:pharmacology; D012680:Sensitivity and Specificity; D020349:Surface Plasmon Resonance / Q000295:instrumentation / Q000379:methods*; D013499:Surface Properties
D000911:Antibodies, Monoclonal; D001672:Biocompatible Materials; D003572:Cytochalasins; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; C007215:cytochalasin E; D000077284:Abciximab